[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Albert Einstein College of Medicine\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":511},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,19,0,[8,45,74,95,121,146,189,214,242,269,296,319,344,368,394,417,438,458,488],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100595462","assessment-of-morbidity-and-mortality-following-serratus-anterior-plane-block-sapb-for-unilateral-rib-fractures-100595462",false,"NCT07032766","Assessment of Morbidity and Mortality Following Serratus Anterior Plane Block (SAPB) for Unilateral Rib Fractures","SAPB","Inclusion Criteria:\n\n* Patients over 18 years of age being treated in the Emergency Department at Jacobi Medical Center\n* Presenting within 24 hours of injury\n* Patient with 2 or more unilateral, anterior or lateral rib fractures\n* Able to provide consent (patient or health care proxy)\n* Clinical team believes the patient will require inpatient admission at the time of enrollment\n\nExclusion Criteria:\n\n* Patients in traumatic arrest or hemodynamic instability\n* Patient expected to be discharged from the hospital within 24 hours\n* Prisoner\n* Pregnancy\n* Children less than 18 years of age\n* The patient is known or is suspected to be allergic to anesthetic\n* Significant pain from another traumatic and distracting injury\n* Patients without the ability to consent (or no health care proxy to consent)\n* Patients with bilateral or posterior rib fractures","ALL","18 Years",{"count":19,"type":20},220,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to learn about the long-term effects of the serratus anterior plane block (SAPB) in adult patients who suffered multiple unilateral anterolateral rib fractures within 24 hours of patient presentation to the emergency department. The main question it aims to answer is:\n\nDoes the SAPB for multiple anterolateral rib fractures demonstrate reduction in patient morbidity and mortality, including incidence of pneumonia, length of hospital stay, discharge disposition, and death, as compared to standard analgesic regimens.\n\nThe SAPB will be performed if a physician trained in the SAPB is available within 24 hours of injury. If a trained physician is not available and the patient meets inclusion criteria, they will receive parental analgesia with opioid therapy. They will be followed until date of hospital discharge, up until 60 days.",[24,25,26],"Pain Management","Rib Fracture Multiple","Serratus Anterior Plane Block",[28,29,30,31],"serratus anterior plane block","rib fractures","mortality","morbidity","RECRUITING","2026-08-17",{"date":35,"type":36},"2026-08-19","ACTUAL",{"date":38,"type":36},"2025-08-10",{"date":40,"type":20},"2027-07",{"name":42,"class":43},"Albert Einstein College of Medicine","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":44},"100610270","designing-a-spatial-navigation-intervention-protocol-informed-by-region-specific-brain-activation-for-mild-cognitive-impairment-100610270","NCT07225400","Designing a Spatial Navigation Intervention Protocol Informed by Region-specific Brain Activation for Mild Cognitive Impairment","SNav","Inclusion Criteria:\n\n* Age 65 and older with amnestic mild cognitive impairment (aMCI);\n* Can speak English;\n* Agrees to MoBI recording;\n* Normal or corrected-to-normal vision\u002Faudition;\n* Able to walk unassisted for 10 minutes;\n* Plan to be in the area for next year\n\nExclusion Criteria:\n\n* Dementia (Memory Impairment\u002FAD8 screen);\n* Medical conditions that affect participation such as vertigo and neck pain;\n* Hospitalization in the past six months or plans for surgery affecting participation in the next four months;\n* Mobility limitations solely due to musculoskeletal limitation or pain;\n* Terminal illness with life expectancy less than 12 months;\n* Presence of clinical disorders that overtly alter attention like delirium;\n* Active psychoses or psychiatric symptoms;\n* Living in nursing home;\n* Participation in intervention trial;\n* Standard contraindications to EEG including seizure medication, epilepsy, stroke, traumatic brain injury;\n* Pregnant women",true,"65 Years",{"count":55,"type":20},30,"INTERVENTIONAL",[58],"NA","The goal of this one-arm clinical trial is to determine whether participants with mild cognitive impairment (MCI) can successfully navigate a virtual reality (VR) maze. The VR maze is designed as a training tool aimed at improving participants' spatial navigation abilities.\n\nMain Aims:\n\n1. To determine whether at least 70% of older adults enrolled in the study can complete twenty-four 50-minute training sessions over a 4-month period.\n2. To assess whether combining virtual reality with EEG recordings can be used to measure brain activation and changes in brain activation associated with spatial navigation learning.\n\nParticipants will:\n\n1. Walk in an open, unobstructed space while wearing VR goggles.\n2. Explore up to fifty different virtual mazes in sequence and attempt to find their way through each one.",[61],"Mild Cognitive Impairment (MCI)",[63,64],"Spatial navigation training","Virtual reality maze design","NOT_YET_RECRUITING","2026-08-07",{"date":68,"type":36},"2026-08-10",{"date":70,"type":20},"2026-10-01",{"date":72,"type":20},"2027-12-23",{"name":42,"class":43},{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":56,"phases":83,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":44},"100341498","phase-i-study-of-fractionated-stereotactic-radiation-therapy-100341498","NCT03726359","Phase I Study of Fractionated Stereotactic Radiation Therapy","Phase I TITE-CREM Dose Escalation Study of Fractionated Stereotactic Radiation Therapy (FSRT) in Unresected Brain Metastases","Inclusion Criteria:\n\n* Pathologically proven diagnosis of a non-hematological malignancy other than small cell lung cancer within 5 years of registration\n* Intact (unresected) brain metastases measuring ≥3 cm and ≤ 6 cm in largest dimension on gadolinium contrast enhanced MRI obtained within 30 days prior to registration OR Surgically resected brain metastasis for which postoperative stereotactic radiotherapy is indicated, with expected target measuring ≥3 cm and ≤6 cm in largest dimension\n* Prior Whole Brain Radiation Therapy (WBRT) is allowed\n* Age ≥ 18 years\n* Women of childbearing potential and male participants must practice adequate contraception\n* History\u002FPhysical examination within 30 days prior to registration\n* Life expectancy \\>3 months\n* Patients are allowed to enroll if previously treated to other lesions with Stereotactic Radiosurgery (SRS)\n* Patients with multiple lesions are allowed, as long there is one dominant lesion that will be treated with FSRT. Other lesions may be treated concurrently with SRS or FSRT at the discretion of the treating physician but will not contribute to the study endpoints\n\nExclusion Criteria:\n\n* Patients with definitive leptomeningeal metastases, based on cerebrospinal fluid (CSF) examination\n* Plan for chemotherapy or targeted agents during treatment. Hormonal therapy, immunotherapy targeting PD-1\u002FPD-L1 axis, and bone supportive therapy may be continued during treatment\n* Contraindication to enhanced MRI imaging such as implanted metal devices. However, patients with implanted devices which are MRI compatible are allowed\n* Patients with measurable brain metastasis resulting from small cell lung cancer and germ cell malignancy\n* Uncontrolled intercurrent illness such as congestive heart failure, unstable angina, cardiac arrhythmia, and uncontrolled seizure activity\n* Previous treatment of the target lesion with radiotherapy",{"count":82,"type":20},43,[58],"There is a lack of prospective trial data and consensus guidelines describing the use of Fractionated Stereotactic Radiation Therapy (FSRT) in the treatment of brain metastases. There has been no prospective dose escalation study performed to date to determine the maximum tolerated dose (MTD) in patients treated with FSRT. Prescription doses in the series described above ranged from 18 Gy to 42 Gy, delivered in 3 to 12 fractions. The results of this study will be used to plan future Phase II\u002FIII studies to determine the efficacy of different dose fractionation schedules of FSRT. The investigator team thus proposes a Phase I study to determine the feasibility and safety of FSRT in patients with brain metastases.",[86],"Brain Metastases","2026-07-31",{"date":89,"type":36},"2026-08-03",{"date":91,"type":36},"2017-12-25",{"date":93,"type":20},"2027-06",{"name":42,"class":43},{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":16,"minAge":102,"maxAge":17,"enrollmentInfo":103,"targetDuration":4,"studyType":56,"phases":105,"briefSummary":106,"conditions":107,"keywords":109,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":44},"100542980","a-pilot-evaluation-of-a-digital-peer-support-intervention-for-suicidal-adolescents-100542980","NCT06349915","A Pilot Evaluation of a Digital Peer Support Intervention for Suicidal Adolescents","SWEEP","Inclusion Criteria:\n\n* past-month history of suicidal thoughts\n* past-month history of Major depressive disorder\n* possession of apple or android smartphone with data plan\n\nExclusion Criteria:\n\n* inability to read\u002Fwrite in English\n* Active mania\n* Active psychosis\n* Autism spectrum disorder","14 Years",{"count":104,"type":20},46,[58],"Suicide risk has increased among youth in underserved communities, where access to mental healthcare is limited. To address this need, the investigator team plans to evaluate the preliminary efficacy of a brief, low-cost, culturally responsive digital intervention for ethnically diverse youth at risk for suicide in The Bronx, New York. In collaboration with community stakeholders, suicide recovery narratives, featuring adolescents' experiences related to recovery from suicidal thoughts will be developed. A smartphone ecological momentary assessment (EMA) app will be used to evaluate whether a curriculum of these narratives provides anti-suicidal benefits to at-risk adolescents.",[108],"Suicide",[110,111,112],"digital intervention","community participation","ecological momentary assessment","2026-07-29",{"date":115,"type":36},"2026-07-30",{"date":117,"type":20},"2026-08",{"date":119,"type":20},"2028-02",{"name":42,"class":43},{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":130,"conditions":131,"keywords":134,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":44},"100099463","examining-genetic-factors-that-affect-the-severity-of-22q112-deletion-syndrome-100099463","NCT00556530","Examining Genetic Factors That Affect the Severity of 22q11.2 Deletion Syndrome","Genetic Modifiers of 22q11.2 Deletion Syndrome","Inclusion Criteria:\n\n* Has 22q11 deletion of 3 megabases (Mb)\n\nExclusion Criteria:\n\n* Has 22q11 deletion smaller than 3 Mb or no deletion",{"count":129,"type":20},1000,"22q11.2 deletion syndrome is a genetic disorder that can cause heart defects, facial abnormalities, and developmental and learning disabilities. The severity of the disorder can vary widely among people. This study will analyze DNA from people with 22q11.2 deletion syndrome to identify genetic variations that may affect the severity of the disorder.",[132,133],"DiGeorge Syndrome","22q11.2 Deletion Syndrome",[135,136,137,138],"Congenital Heart Defects","Single Nucleotide Polymorphisms","Copy Number Variations","Whole Genome Association Study","2026-07-28",{"date":113,"type":36},{"date":142,"type":4},"2016-07",{"date":144,"type":20},"2029-06",{"name":42,"class":43},{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":52,"sex":153,"minAge":154,"maxAge":155,"enrollmentInfo":156,"targetDuration":4,"studyType":56,"phases":158,"briefSummary":160,"conditions":161,"keywords":169,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":44},"100633458","phase-4-vaginal-estradiol-vs-moisturizer-to-improve-postmenopausal-vaginal-aging-symptoms-and-the-microbiome-in-women-living-with-hiv-100633458","NCT07526948","Vaginal Estradiol vs Moisturizer to Improve Postmenopausal Vaginal Aging Symptoms and the Microbiome in Women Living With HIV","Vaginal Estradiol Versus Moisturizer to Improve Postmenopausal Vaginal Aging Symptoms, Dysbiosis and Markers of Latency Reversal in Menopausal Women Living With HIV","Inclusion Criteria:\n\n* female\n* at least 40 years old\n* menopausal (no menses in 12 months) within 2 years of last menstrual period or perimenopausal in the late menopausal transition, defined as an interval of amenorrhea greater than or equal to 60 days\n* have symptoms of the genitourinary syndrome of menopause (GSM) which developed within the prior 2 years. Symptoms of GSM include vaginal symptoms including dryness, soreness, itching, irritation and dyspareunia and\u002For urinary symptoms including urgency, frequency and recurrent urinary tract infections (UTIs)\n\nExclusion Criteria:\n\n* Unexplained or unevaluated abnormal genital bleeding\n* Current or suspected pregnancy\n* Desired pregnancy\n* If less than 55 years old, have had a hysterectomy and have at least one ovary (as menopause cannot be determined in this case by amenorrhea alone)\n* Pelvic or vaginal surgery in the prior 60 days\n* Used systemic reproductive hormones in the last 2 months\n* Used antibiotics in the last 30 days\n* Used immunosuppressive medications in the prior 60 days including biologics, chemotherapeutics or post transplant immunosuppressive medications\n* Used any vaginal or vulvar preparations in the last month\n* Current active vaginal infection diagnosed at study entry\n* Any serious disease or condition that may interfere with study compliance\n* Current or previous history of breast cancer or estrogen dependent cancer (e.g., ovarian, endometrial)\n* Current or previous history of deep vein thrombosis or pulmonary embolism\n* Current or previous history of myocardial infarction or stroke\n* Known clotting disorder including Protein C, Protein S and antithrombin deficiency, Factor V Leiden or prothrombin mutations\n* Known severe liver disease including cirrhosis or active Hepatitis B\n* Known allergic reaction to Vagifem (estradiol vaginal tablet) or Replens","FEMALE","40 Years","70 Years",{"count":157,"type":20},62,[159],"PHASE4","This is a research study about the effects of vaginal estradiol compared to moisturizer on vaginal symptoms of menopause and the microbiome in women with HIV. This research study aims to understand how vaginal products affect the aging of the female genital tract in women living with HIV who are menopausal or perimenopausal and have vaginal or urinary symptoms. There is a comparison group of women who are living without HIV. Participants with HIV and vaginal or urinary menopausal symptoms (e.g., dryness, irritation, soreness, itching, pain with sex, dysuria, urgency, or frequent urinary tract infections) will be asked to apply vaginal estradiol or a vaginal moisturizer (Replens). Participants who have vaginal or urinary menopausal symptoms and do not have HIV will receive vaginal estradiol.",[162,163,164,165,166,167,168],"Menopausal Complaints","Vaginal Atrophy","Genitourinary Symptoms","HIV (Human Immunodeficiency Virus)","Menopause Related Conditions","Vaginitis","Perimenopause",[170,171,172,173,174,175,176,177,178,179,180,181],"Pain with sex","Vaginal dryness","Symptoms of menopause","HIV Infection","Menopause","Vaginal microbiome","Dysbiosis","Aging","Premature aging","Atrophic vaginitis","Genitourinary syndrome of menopause (GSM)","Symptoms of perimenopause","2026-07-27",{"date":139,"type":36},{"date":185,"type":20},"2026-09",{"date":187,"type":20},"2029-10-14",{"name":42,"class":43},{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":195,"eligibilityCriteria":196,"healthyVolunteers":52,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":197,"targetDuration":4,"studyType":56,"phases":199,"briefSummary":200,"conditions":201,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":44},"100628637","improving-clinic-delivery-of-hiv-related-anal-health-services-100628637","NCT07464236","Improving Clinic Delivery of HIV-related Anal Health Services","Partnering to Enhance Anal Health Communication and HIV-related Evidence-based Services","PEACHES 2","Inclusion Criteria:\n\nStaff participants (\"Strategy Recipients\" and \"Strategy Recipients\")\n\n* employed at one of eight Coastal Family Health Center clinics at the time of the survey\n* over age 18 years old\n\nPatient participants (\"Patients\")\n\n* accessing sexual health services at one of eight Coastal Family Health Center clinics in the last 12 months\n* over 18 years old\n\nExclusion Criteria:\n\n* Staff or patients who are unable to provide informed consent (e.g., significant cognitive impairment)\n* Individuals currently incarcerated or in state custody\n* Patients whose only visits are for non-HIV, non-STI issues and who do not meet the EMR-based eligibility criteria above",{"count":198,"type":20},8,[58],"This project will test ways to reduce stigma in healthcare settings so that more providers offer, and more patients receive, important anal sex-related HIV services, including anorectal sexually transmitted infection (STI) testing, preventive medications, and cancer screening. By evaluating these stigma-reduction strategies in eight clinics in the Mississippi Delta, a region with high rates of HIV and STIs, the research team will learn whether and how these approaches work to improve access to care. The results will help guide healthcare systems in using the most effective methods to reduce stigma, making it easier for people to get prevention services and improving public health.",[202,203,204,205],"HIV","Gonorrhea","Chlamydia","Anal Cancer Squamous Cell","2026-06-02",{"date":208,"type":36},"2026-06-03",{"date":210,"type":20},"2026-08-01",{"date":212,"type":20},"2030-07-31",{"name":42,"class":43},{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":218,"acronym":4,"eligibilityCriteria":219,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":155,"enrollmentInfo":220,"targetDuration":4,"studyType":56,"phases":222,"briefSummary":223,"conditions":224,"keywords":230,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":44},"100555510","milk-for-diabetes-prevention-100555510","NCT06513026","Milk for Diabetes Prevention","Inclusion Criteria:\n\n* LNP genotype (LCT gene rs4988235, GG genotype)\n* History of pre-diabetes, defined as fasting blood glucose 100-125 mg\u002FdL and\u002For hemoglobin A1c (HbA1c) 5.7-6.4% and have not been diagnosed with diabetes nor take diabetes medication (pre-diabetes determined at most recent study visit \\[for HCHS\u002FSOL participant\\] or most recent medical chart or self-report \\[for other participant\\])\n* Drink ≤1 cup milk\u002Fday\n* Basic computer or smartphone skills\n* Can speak and read English fluently\n\nExclusion Criteria:\n\n* Diabetes diagnosis\n* Taking anti-diabetes medication\n* Cancer, cardiovascular disease (CVD), or life-threatening illness\n* Known milk allergy\n* Has severe GI symptoms after drinking milk\n* History of GI surgery\n* Had a double mastectomy\n* Smoking\n* More than 1 alcoholic beverage\u002Fday\n* Pregnant or breastfeeding\n* Colonoscopy in last 2 weeks\n* Antibiotics in last 3 months\n* Taking probiotics or fiber supplements (if taking, must be able to stop taking during study)\n* Taking laxatives, stool softeners, anti-diarrheal (if taking, must be able to stop taking during study)\n* Taking lactase pills (if taking, must be able to stop taking)\n* Participating in extreme dieting program\n* Planning extended travel that would prevent participation in study\n* Taking medication that must be taken separate from calcium or dairy products",{"count":221,"type":20},40,[58],"Individuals with lactase non-persistence (LNP; determined by a functional variant in the LCT gene \\[rs4988235, GG genotype\\]) are susceptible to lactose intolerance in adulthood due to deficiency of lactase, the enzyme which digests milk lactose sugars. However, many LNP individuals still drink ≥1 cup of milk daily. Recent analysis in the Hispanic Community Health Study\u002FStudy of Latinos (HCHS\u002FSOL) found that consumption of 1 serving (cup) of milk\u002Fday was associated with \\~30% lower risk of type 2 diabetes among LNP individuals, but not among individuals with lactase persistence (LP). This beneficial effect might be partially explained by favorable alterations in gut microbiota and related metabolites associated with higher milk consumption among LNP individuals. Based on these observational study findings, the investigator team proposes to conduct a randomized, controlled trial of lactose-containing vs. lactose-free milk in LNP individuals with pre-diabetes, to comprehensively investigate the effects of milk intake on the gut microbiome and glycemic outcomes.",[225,226,227,228,229],"Lactose Intolerance","Lactose Intolerant","Lactase Persistence","Pre-Diabetes","Diabetes Mellitus, Type 2",[231,232,233],"Lactose","Lactose-free","Lactase Non Persistence","2026-05-21",{"date":236,"type":36},"2026-05-26",{"date":238,"type":36},"2026-05-15",{"date":240,"type":20},"2028-04",{"name":42,"class":43},{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":246,"acronym":247,"eligibilityCriteria":248,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":249,"targetDuration":4,"studyType":56,"phases":251,"briefSummary":252,"conditions":253,"keywords":256,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":44},"100561458","therapeutic-drug-monitoring-for-linezolid-in-the-treatment-of-rifampin-resistant-tuberculosis-100561458","NCT06590428","Therapeutic Drug Monitoring for Linezolid in the Treatment of Rifampin-resistant Tuberculosis","THERMOL","Inclusion Criteria:\n\n* Adult male or female patient \\> 18 years of age\n* Microbiological confirmation of rifampicin-resistant tuberculosis (e.g., phenotypic or genotypic drug susceptibility testing, GeneXpert MTB\u002FRIF™). Participants may have resistance to additional medications as well - i.e., MDR and XDR TB - but must have resistance to at least rifampin\n* Initiated on a rifampicin-resistant tuberculosis (RR-TB) treatment regimen containing linezolid, no more than 14 days prior to randomization\n* HIV status is known and confirmed\n\n  * Both HIV-positive and HIV-negative individuals are eligible\n  * If an individual reports unknown HIV status, they must consent to HIV testing at time of enrollment to confirm status. If they decline to be tested, they are not eligible for the study\n\nExclusion Criteria:\n\n* Severe medical condition with expected death in the next 7 days\n* Pregnant at time of screening\n* Initial linezolid dose \\\u003C 600mg daily\n* Severe form of extrapulmonary TB (i.e., meningitis, pericarditis, or osteomyelitis)\n* Unlikely to follow-up at Nkqubela Hospital based on location of residence",{"count":250,"type":20},280,[58],"This study is a two-arm, pragmatic, open-label, randomized clinical trial to determine the efficacy of Therapeutic Drug Monitoring (TDM) in preventing premature discontinuation of Linezolid (LZD) in participants with Rifampicin-resistant tuberculosis (RR-TB). Following the initiation of treatment, participants will be monitored throughout the approximate 6-month duration of RR-TB therapy.",[254,255],"Rifampin-resistant Tuberculosis","Drug-resistant Tuberculosis",[257,258,259,260],"HIV Status","Therapeutic Drug Monitoring","anti-Tuberculosis activity","Linezolid","2026-04-28",{"date":263,"type":36},"2026-05-04",{"date":265,"type":36},"2026-04-07",{"date":267,"type":20},"2029-12",{"name":42,"class":43},{"id":270,"slug":271,"hasResults":11,"nctId":272,"briefTitle":273,"officialTitle":273,"acronym":4,"eligibilityCriteria":274,"healthyVolunteers":52,"sex":16,"minAge":275,"maxAge":155,"enrollmentInfo":276,"targetDuration":4,"studyType":56,"phases":278,"briefSummary":280,"conditions":281,"keywords":284,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":44},"100327259","phase-2-regulation-of-endogenous-glucose-production-by-central-katp-channels-100327259","NCT03540758","Regulation of Endogenous Glucose Production by Central KATP Channels","Inclusion Criteria:\n\nFor healthy (non-diabetic) participants:\n\n* Age: 21-70 years old\n* Body Mass Index (BMI) under 40 kg\u002Fm\\^2\n* Negative drug screen (see below)\n* Normal Hemoglobin A1c (HbA1c) and fasting glucose\n* In general good health (see below for exclusions)\n* Not participating in any other research study besides those done by the study team\n\nFor T2D participants:\n\n* Age: 21-70 years old\n* BMI under 40 kg\u002Fm\\^2\n* Stable and moderate-to-poor glycemic control (HbA1c: 8.0-12.0%)\n* Negative drug screen (see below)\n* Not suffering from a previously diagnosed proliferative retinopathy, significant diabetic renal disease (urinary microalbumin \\\u003C100 μg\u002Fdl) or severe peripheral neuropathy (including cardiovascular and gastrointestinal autonomic neuropathy) per medical history\n* Diabetic subjects will be otherwise in good health (see below for exclusions), taking no medications that might affect study eligibility based on review by study doctor, and not participating in any other research study besides those done by the study team\n\nExclusion Criteria:\n\n* Age: Under 21 or over 70 years old\n* BMI: \\>40 kg\u002Fm\\^2 for Type 2 Diabetes (T2D) and Non-Diabetic (ND) subjects\n* Blood pressure \\>150\u002F90 or \\\u003C90\u002F60 on more than one occasion\n* Severe polydipsia and polyuria (in subjects with T2D). Since polydipsia and polyuria are common symptoms of T2D, the distinction \"severe\" denotes that the subject indicates a worsening in the symptoms and\u002For an experience of discomfort related to the symptoms at the time of screening and\u002For at the time of withdrawal from the medications\n* Urine microalbumin: \\>300 mg\u002Fg of creatinine (in subjects with T2D)\n* Uncontrolled hyperlipidemia defined as Triglycerides (TG) \\> 400 mg\u002FdL and\u002For Total Cholesterol \\>300 mg\u002FdL\n* Clinically significant liver dysfunction including thrombocytopenia (platelets \\\u003C100,000\u002FuL), anemia (as below), hypoalbuminemia (\\\u003C3.5 g\u002FdL), coagulopathy (INR \\> 1.5), and\u002For liver enzymes more than 3 times the upper limit of normal\n* Clinically significant kidney dysfunction, Glomerular Filtration Rate (GFR): \\\u003C60 mg\u002FdL\n* Clinically significant anemia. Prospective subjects with hemoglobin below the lower limit of 12 g\u002Fdl for for men and 11 g\u002FdL for women will be assessed with history and physical exam to rule out clinically significant anemia, defined as an individual with symptoms (e.g., fatigue, weakness, shortness of breath, palpitations), signs (pallor, brittle nails etc.), or currently under treatment for anemia. In the absence of a documented hemoglobin decrease or iron deficiency, subjects will not be excluded\n* Clinically significant leukocytosis or leukopenia\n* Clinically significant thrombocytopenia or thrombocytosis\n* Coagulopathy\n* Urine drug screen positive for any of the following: amphetamines, barbiturates, benzodiazepines, cocaine, methadone, opiates, oxycodone, phencyclidine (PCP). Amphetamines, oxycodone, opiates, methadone, and benzodiazepines have been shown to affect glucose metabolism (increased glycemia, increased fasting insulin levels, delayed insulin response to food ingestion, insulin deficiency). As the drug test available in the Clinical Research Center (CRC) is a 7-drug panel, the investigator team cannot specifically choose which drugs are screened for. Additionally, in the interest of selecting patients on the basis of their reliability and dependability, the investigator team would like to exclude participants using illicit drugs. Occasional use of cannabis (once or twice per week) is not an exclusion factor. If the test is read as \"indeterminate\" it will be repeated at the bedside and an additional sample will be sent to the lab. Decision to enroll subject that day prior to results from lab being available will be decided on a case-by-case basis, i.e., when all previous drug testing had been negative and clinical suspicion is very low\n* Urinalysis: Clinically significant abnormalities\n* Clinically significant electrolyte abnormalities\n* Smoking \\>10 cigarettes\u002Fday\n* Alcohol: Men \\>14 drinks\u002Fweek or \\>4 drinks\u002Fday, Women \\>7 drinks\u002Fweek or \\>3 drinks\u002Fday\n* History of chronic liver disease, active hepatitis infection, HIV\u002FAIDS, chronic kidney disease (stage 3 or greater), active cancer, cardiovascular disease or other heart disease, systemic rheumatologic conditions, seizures, bleeding disorders, muscle disease\n* Surgeries that involve removal of endocrine glands except for thyroidectomy (if euthyroid on thyroid hormone replacement - if such history free thyroxine (fT4) and Thyroid Stimulating Hormone (TSH) will be checked)\n* Pregnant women\n* Subject enrolled in another study less than one month prior to the anticipated start date of the proposed study, besides those done by our group\n* Family history of premature cardiac death\n* Allergies to medication administered during study\n* Uncontrolled psychiatric disorders\n* Any condition which in the opinion of the PI makes the subject ill suited for participation in the study","21 Years",{"count":277,"type":20},100,[279],"PHASE2","Type 2 diabetes (T2D) affects the ability of the body to process glucose (sugar). Under fasting conditions, the liver is able to make sugar to maintain glucose levels in an important process called endogenous glucose production (EGP). Previous studies suggest that the central nervous system (CNS), including the brain, helps to regulate levels of glucose in the body by communicating with the liver. This process can be impaired in people with type 2 diabetes, and can contribute to the high level of glucose seen in these individuals.\n\nThe purpose of this study is to understand how activating control centers of the brain with a medication called diazoxide can affect how much glucose (sugar) is made by the liver. This is particularly important for people with diabetes who have very high production of glucose, which in turn can lead to diabetes complications.",[282,283],"Diabetes Mellitus","Glucose Metabolism Disorders",[285,286,287,288],"Central KATP Channels","diabetes","diazoxide","endogenous glucose production","2026-04-23",{"date":261,"type":36},{"date":292,"type":36},"2018-08-01",{"date":294,"type":20},"2027-04",{"name":42,"class":43},{"id":297,"slug":298,"hasResults":11,"nctId":299,"briefTitle":300,"officialTitle":301,"acronym":4,"eligibilityCriteria":302,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":303,"targetDuration":4,"studyType":56,"phases":305,"briefSummary":306,"conditions":307,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":318},"100478841","5-cog-20-a-pragmatic-clinical-trial-100478841","NCT05515224","5-Cog 2.0: A Pragmatic Clinical Trial","5-Cog Paradigm to Improve Detection of Cognitive Impairment in Primary Care: Pragmatic Clinical Trial","Inclusion Criteria:\n\n1. 65 years and older\n2. Presence of cognitive concerns\n3. English or Spanish speaking.\n4. Able to see and hear well enough to complete assessments.\n\nExclusion Criteria:\n\n1. Prior diagnosis of dementia (documented in the electronic medical record or reported by physicians).\n2. Permanent nursing facility residents.",{"count":304,"type":20},6600,[58],"Cognitive impairment related to dementia is frequently under-diagnosed in primary care settings. This problem is more prevalent in health disparities populations. The investigators developed the 5-Cog brief cognitive assessment that is simple to use, standardized, takes \\\u003C5 minutes, does not require informants, and accounts for major technical, cultural, and logistical barriers of current assessments. The investigators propose a hybrid Type 1 effectiveness-implementation design in real-world settings to adapt and test the effectiveness of the 5-Cog paradigm to increase detection of cognitive impairment care in older adults presenting with cognitive concerns.\n\nThe study aim is to evaluate, using a pragmatic cluster-randomized trial design, the effectiveness of the 5-Cog paradigm to increase 'incident cognitive impairment' detection (new MCI and dementia diagnoses) relative to enhanced usual care in 6,600 older patients presenting with cognitive concerns in 22 primary care clinics in Bronx and Indiana. As diagnosis without action will not improve patient care, 'improved dementia care' will be examined as a secondary outcome. Results will also be examined in NIH designated health disparity populations including underserved minority and socio-economically challenged populations.",[308,309],"Dementia","Cognitive Impairment","2026-04-14",{"date":312,"type":36},"2026-04-17",{"date":314,"type":36},"2023-08-18",{"date":316,"type":20},"2027-11",{"name":42,"class":43},2,{"id":320,"slug":321,"hasResults":11,"nctId":322,"briefTitle":323,"officialTitle":324,"acronym":4,"eligibilityCriteria":325,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":326,"targetDuration":4,"studyType":56,"phases":327,"briefSummary":328,"conditions":329,"keywords":333,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":337,"lastUpdatePostDateStruct":338,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":343,"locationsCount":44},"100584041","cvcs-versus-midline-catheters-100584041","NCT06884176","CVCs Versus Midline Catheters","Complication Rates Associated With Central Venous Catheters Versus Midline Catheters: A Randomized Control Trial","Inclusion Criteria:\n\n* Patients over 18 years of age being treated in the Emergency Department at Jacobi Medical Center\n\n  * Have an upper extremity (left or right arm) that can accept a midline catheter\n  * Able to provide consent (patient or health care proxy)\n  * Clinical team believes the patient will require inpatient admission at the time of needing intravenous access\n  * Requires a central line or midline catheter as an expected requirement of care\n* Patients requiring a single vasopressor due to hypotension\n\nExclusion Criteria:\n\n* Patients in cardiac arrest (prior to achieving ROSC)\n* Patients with infection or burns at both upper extremities\n* Patient expected to be discharged from the hospital within 24 hours\n* Prisoner\n* Pregnancy\n* Children less than 18 years of age\n* The patient is known or is suspected to be allergic to materials contained in the device\n* Patients known to have bacteremia\n* Patients with existing central venous catheter\n* Patients without the ability to consent (or no health care proxy to consent)",{"count":277,"type":20},[58],"The goal of this clinical trial is to learn if midline catheters can reduce adverse patient outcomes in adult patients requiring a single vasopressor. The main questions the study aims to answer are:\n\n* Do midline catheters reduce the rates of catheter-related bloodstream infections as compared to central venous catheters?\n* Do midline catheters reduce the rates of deep venous thrombosis as compared to central venous catheters? Researchers will compare midline catheters to central venous catheters to see if there is a reduction in these events.\n\nParticipants will be randomized to the midline catheter group or the central venous catheter group. The catheters will be part of standard of care for vasopressor therapy. The participants will be followed for 30 days.",[330,331,332],"Central Venous Catheter","Midline Catheter","Complication of Catheter",[334,335,336],"midline catheter","central venous catheter","central line related bloodstream infection","2026-04-01",{"date":339,"type":36},"2026-04-02",{"date":341,"type":20},"2026-06",{"date":93,"type":20},{"name":42,"class":43},{"id":345,"slug":346,"hasResults":11,"nctId":347,"briefTitle":348,"officialTitle":349,"acronym":4,"eligibilityCriteria":350,"healthyVolunteers":11,"sex":153,"minAge":17,"maxAge":351,"enrollmentInfo":352,"targetDuration":4,"studyType":56,"phases":354,"briefSummary":355,"conditions":356,"keywords":358,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":361,"startDateStruct":363,"completionDateStruct":365,"leadSponsor":367,"locationsCount":44},"100556422","reiki-breast-surgery-qol-project-for-women-undergoing-breast-surgery-100556422","NCT06524895","Reiki Breast Surgery QOL Project for Women Undergoing Breast Surgery","Pilot Study of Medical Reiki for Women Undergoing Surgery for Breast Cancer: Impact on Quality of Life, Medical Recovery Metrics, and Cortisol","Inclusion Criteria:\n\n* Ages 18-99\n* Breast Cancer Diagnosis Stage 0-III\n* Undergoing unilateral or bilateral mastectomy (with or without reconstruction) within 2 weeks of recruitment\n* English Speaking\n* From within 50 miles of Bronx County, NY\n\nExclusion Criteria:\n\n* Current, uncontrolled psychiatric co-morbidities\n* Pregnant women","99 Years",{"count":353,"type":20},32,[58],"This pilot study will examine the impact of pre-operative Medical Reiki© on the psychosocial well-being and recovery of underserved women undergoing breast cancer surgery.",[357],"Breast Cancer",[359],"Reiki","2026-03-03",{"date":362,"type":36},"2026-03-04",{"date":364,"type":36},"2022-11-09",{"date":366,"type":20},"2026-11",{"name":42,"class":43},{"id":369,"slug":370,"hasResults":11,"nctId":371,"briefTitle":372,"officialTitle":373,"acronym":4,"eligibilityCriteria":374,"healthyVolunteers":52,"sex":16,"minAge":375,"maxAge":376,"enrollmentInfo":377,"targetDuration":4,"studyType":56,"phases":379,"briefSummary":380,"conditions":381,"keywords":383,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":388,"startDateStruct":390,"completionDateStruct":392,"leadSponsor":393,"locationsCount":44},"100537944","centralized-screening-unit-csu-at-montefiore-einstein-100537944","NCT06284408","Centralized Screening Unit (CSU) at Montefiore-Einstein","Implementation of a Centralized Screening Unit at Montefiore-Einstein","Inclusion Criteria:\n\nClinic level:\n\n* a NYC RING affiliated clinic,\n* Opt into and agree to research protocol;\n\nPatient level:\n\n* Age 50-77 for participants,\n* past or current smoker,\n* 20+ pack-years tobacco,\n* has quit smoking within the last 15 years,\n* without chest CT within the past 12 months, and,\n* no history of lung cancer or and at least 5 years since the diagnosis of any other malignancy\n\nExclusion Criteria:\n\nClinic level:\n\n* only treats pediatric patients,\n* Opt out of research protocol;\n\nPatient level:\n\n* Primary care provider instruction to not contact an individual for any reason. Any individual inadvertently contacted who does not meet these criteria will be excluded from the study.","50 Years","77 Years",{"count":378,"type":20},9460,[58],"This study proposes to increase Lung-cancer screening (LCS) in the Bronx, New York. Despite strong evidence that Lung-cancer screening (LCS) can reduce Lung cancer (LCa) deaths, low-dose computed tomography (LDCT) referral rates by clinicians are very low and there is poor adherence with LCS by patients. Both provider and patient barriers may be amenable to systemic improvements in support, coordination and infrastructure for screening. The investigator team hypothesizes that the implementation of a Central Screening Unit (CSU) that shifts routine workflow attributed to LCS (e.g., collection of smoking history, determination of eligibility, shared decision making and arranging follow-up) away from busy practices (usual care) and that offers patients an array of navigation and support services will increase the uptake of LCS guidelines and subsequent low-dose computed tomography (LDCT) screening scans in a low-income, predominately Hispanic and Black catchment area. The proposed study represents a unique opportunity to test this hypothesis in the context of the roll out of a CSU as a significant new component of the Montefiore-Einstein health system. The investigator team will examine whether and how the CSU facilitates LCS uptake and retention of patients. This study is powered to test whether CSU reduces proportion of late-stage lung cancer diagnoses in the Bronx, New York.",[382],"Lung Cancer",[384,385,386],"Lung Cancer Screening (LCS)","Low dose computed tomography (LDCT)","Centralized Screening Unit (CSU)","2026-01-22",{"date":389,"type":36},"2026-01-23",{"date":391,"type":36},"2025-02-24",{"date":144,"type":20},{"name":42,"class":43},{"id":395,"slug":396,"hasResults":11,"nctId":397,"briefTitle":398,"officialTitle":399,"acronym":400,"eligibilityCriteria":401,"healthyVolunteers":11,"sex":16,"minAge":275,"maxAge":4,"enrollmentInfo":402,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":404,"conditions":405,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":410,"lastUpdatePostDateStruct":411,"startDateStruct":413,"completionDateStruct":415,"leadSponsor":416,"locationsCount":44},"100504917","cough-capture-as-a-portal-into-the-lung-100504917","NCT05854563","Cough Capture as a Portal Into the Lung","Genetics of Lung Disease (Exhaled Breath DNA Methylation in Lung Carcinogenesis)","CC1","Inclusion Criteria:\n\n* Age: minimum age of 21 years\n* Gender: Male and Female adults\n* Ethnicity: All ethnic groups and races\n* Subjects undergoing bronchoscopy for diagnostic purposes or therapy\n* Subjects without a known diagnosis of lung cancer who are not scheduled for lung tissue collection procedures\n* Subjects with a known or suspected diagnosis of asthma or COPD and are scheduled for a visit at Montefiore Asthma or COPD Center and individual practices, and\u002For in-hospital with exacerbation\n\nExclusion Criteria:\n\n* Bleeding diathesis or known coagulopathy precluding clinically indicated biopsy (e.g., INR\\>1.3, PTTr\\>1.3), thrombocytopenia \\\u003C50,000, uremia with serum creatinine \\>3.0\n* Unstable angina\n* Recent myocardial infarction (within 3 months),\n* Uncontrolled congestive heart failure or severe pulmonary hypertension (mean PAP\\>75 mmHg)",{"count":403,"type":20},2000,"The lung is a privileged organ; blood does not reflect most lung processes well, if at all. Therefore, for population scale diagnostics, the investigator team is developing non-invasive portals to the lung, for eventual early detection\u002Frisk assessment and diagnostic purposes. However, large macromolecules are not likely suspended nor readily detected in the breath. In particular, genomic DNA in the breath condensate (EBC) is very sparse, and where present, generally highly fragmented, not readily amenable to sequencing based assessments of DNA somatic mutation burden or distribution. Because gDNA (and protein) is challenging to obtain non-invasively from EBC, the study team considered alternative surrogate lower airway specimens. Cough capture is rarely done, and the investigator team is in the process of optimizing its collection. Importantly, the team will be evaluating how much of coughed material is from saliva contamination. Additionally, analyzing material that is target captured by capturing deep lung extracellular vesicles (EVs) using immobilized CCSP\u002FSFTPC antibodies targeting EVs from distal bronchiole Club and alveolar type 2 cells could circumvent the mouth contamination problem, leaving a non-invasive portal to the deep lung suitable for large molecules, and in turn suitable for myriad epidemiologic and clinical applications.\n\nThe investigator team proposes (Aim 1) to pursue optimizing cough collection, and testing the efficacy and practicality of partitioning cough specimen for deep-lung specific extra-cellular vesicles (EVs). This cough specimen will be compared to that from invasively collected deep lung samples BAL\u002Fbronchial brushings, and to the potential contaminating mouth rinse, all from the same individuals. (Aim 2) The study team initially proposes to examine these cough specimens for somatic mutations by SMM bulk sequencing for single nucleotide variation, developed in the Vijg\u002FMaslov labs. Finally, the investigator team will (Aim 3) test all airway specimens (cough, mouthwash and BAL) for lung surrogacy of cough, using proteins known to be specific for lung, as opposed to oral cavity\u002Fsaliva, in the Sidoli\u002Fproteomics core.\n\nThe investigator team envisions that the translational impact of non-invasively obtained DNA or protein markers could allow for more rapid acute clinical diagnoses, and facilitate precision prevention and\u002For early detection of many acute and chronic respiratory disorders, including lung cancer, asthma and COPD, acute and chronic infectious diseases, and indeed systemic disorders of inflammation and metabolism.",[406,382,407,408,409],"Lung Diseases","Lung Diseases, Obstructive","Lung Diseases, Interstitial","Lung Inflammation","2026-01-12",{"date":412,"type":36},"2026-01-13",{"date":414,"type":36},"2023-03-28",{"date":93,"type":20},{"name":42,"class":43},{"id":418,"slug":419,"hasResults":11,"nctId":420,"briefTitle":421,"officialTitle":421,"acronym":4,"eligibilityCriteria":422,"healthyVolunteers":11,"sex":16,"minAge":423,"maxAge":4,"enrollmentInfo":424,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":425,"conditions":426,"keywords":428,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":430,"lastUpdatePostDateStruct":431,"startDateStruct":433,"completionDateStruct":435,"leadSponsor":437,"locationsCount":44},"100243030","hematology-biobank-in-vitro-study-of-blood-disorders-100243030","NCT02442011","Hematology Biobank: In Vitro Study of Blood Disorders","Inclusion Criteria:\n\n* Above 12 years of age and referred to the Hematology Division at Montefiore-Einstein\n* Under the care of a Montefiore-Einstein hematologist for a hematologic disorder\n\nExclusion Criteria:\n\n\\- Do not meet the Inclusion Criteria listed above","12 Years",{"count":403,"type":20},"This is a biorepository of blood specimens from subjects with different Hematological disorders.",[427],"Hematological Disorders",[429],"Hematology Biobank","2026-01-02",{"date":432,"type":36},"2026-01-06",{"date":434,"type":4},"2014-01",{"date":436,"type":20},"2030-01",{"name":42,"class":43},{"id":439,"slug":440,"hasResults":11,"nctId":441,"briefTitle":442,"officialTitle":443,"acronym":4,"eligibilityCriteria":444,"healthyVolunteers":52,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":445,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":446,"conditions":447,"keywords":449,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":451,"lastUpdatePostDateStruct":452,"startDateStruct":453,"completionDateStruct":455,"leadSponsor":457,"locationsCount":318},"100110848","the-longevity-genes-in-founder-populations-project-100110848","NCT00707694","The Longevity Genes in Founder Populations Project","Searching for Longevity Genes in the Historically Unique Ashkenazi Jewish Population","Inclusion Criteria:\n\n* Ashkenazi Jewish, age 95+,\n* Offspring of person age 95+,\n* Offspring of parents who died age 70 or younger.\n\nExclusion Criteria:\n\n* Non-Ashkenazis",{"count":403,"type":20},"We believe extreme longevity is due to specific genes which function to delay aging and prevent disease. The purpose of the research is to identify the genes\u002Fmutations associated with healthier aging; to understand the biological functions of these genes\u002Fmutations; and to develop therapies to replicate these preservative genetic activities in individuals who do not have the genetic profile for longevity.",[448],"Extreme Longevity",[450],"95 years of age and older","2025-12-30",{"date":430,"type":36},{"date":454,"type":36},"1998-07",{"date":456,"type":20},"2032-12",{"name":42,"class":43},{"id":459,"slug":460,"hasResults":11,"nctId":461,"briefTitle":462,"officialTitle":463,"acronym":464,"eligibilityCriteria":465,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":466,"enrollmentInfo":467,"targetDuration":4,"studyType":56,"phases":469,"briefSummary":470,"conditions":471,"keywords":474,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":480,"lastUpdatePostDateStruct":481,"startDateStruct":483,"completionDateStruct":485,"leadSponsor":487,"locationsCount":318},"100495677","telemedicine-delivered-unified-protocol-for-cognitive-behavioral-therapy-for-anxiety-and-depression-100495677","NCT05734313","Telemedicine-Delivered Unified Protocol for Cognitive Behavioral Therapy for Anxiety and Depression","Telemedicine-Delivered Unified Protocol for Cognitive Behavioral Therapy for Anxiety and Depression in Young Adults With Type 1 Diabetes","UP-CBT","Inclusion Criteria:\n\n* Type 1 diabetes (T1D) duration ≥ 6 months\n* 18-64 years old\n* English- or Spanish-speaking\n* Anxiety or depressive mood disorder as per structured diagnostic interview.\n\nExclusion Criteria:\n\n* Developmental or sensory disability interfering with participation\n* Current pregnancy\n* Bipolar disorders, psychotic disorders, severe eating disorders, severe substance abuse disorders, or acute suicidal risk or self-harm\n* Use of medications or recent medical procedures that would impact glycemic control or use of continuous glucose monitoring (CGM) over the study\n* Received cognitive behavioral therapy (CBT) in last year or plans to initiate CBT; (6) temporary exclusion for recent initiation of psychotropic medication - must be on a stable dose for 6 weeks prior to enrollment.","64 Years",{"count":468,"type":20},94,[58],"This project will evaluate a telemedicine-delivered, Unified Protocol for Cognitive-Behavioral Therapy (UP-CBT) enhanced with continuous glucose monitor (CGM) review to target anxiety and depressive symptoms and glycemic control in adults with type 1 diabetes.",[472,473],"Diabetes","Type 1 Diabetes",[472,473,475,476,477,478,479],"Depression","Anxiety","Diabetes Distress","Diabetes Management","Diabetes Self-Care","2025-10-29",{"date":482,"type":36},"2025-10-30",{"date":484,"type":36},"2023-03-31",{"date":486,"type":20},"2027-12",{"name":42,"class":43},{"id":489,"slug":490,"hasResults":11,"nctId":491,"briefTitle":492,"officialTitle":493,"acronym":4,"eligibilityCriteria":494,"healthyVolunteers":11,"sex":153,"minAge":17,"maxAge":4,"enrollmentInfo":495,"targetDuration":497,"studyType":21,"phases":4,"briefSummary":498,"conditions":499,"keywords":500,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":503,"lastUpdatePostDateStruct":504,"startDateStruct":506,"completionDateStruct":508,"leadSponsor":510,"locationsCount":44},"100438806","intra-operative-radiation-registry-100438806","NCT04994067","Intra-Operative Radiation Registry","Intra-Operative Radiation Therapy (IORT) Using the IntraBeam® System - A Registry Protocol","Inclusion Criteria:\n\n* Female gender\n* Age ≥ 45\n* cT1-2N0, \\\u003C3.5cm invasive breast cancer, estrogen-receptor positive or DCIS of breast, Grade 1-2, mammographically detected, \\\u003C 2.5 cm, estrogen-receptor positive\n* Suitable for breast conserving surgery\n* No contraindication to radiation\n* Mammogram within 6 months of planned procedure\n* Fitness for lumpectomy under general anesthesia\n* Planned to receive IORT\n\nExclusion criteria\n\n* Known axillary lymph node positive breast cancer (negative biopsy not required)\n* Multicentric cancer in the same breast as diagnosed by clinical examination, mammography, ultrasound, MRI or pathologic assessment, not amenable to excision with negative margins with a single lumpectomy.\n* Patients known to have BRCA 1\u002F2 (breast cancer 1, breast cancer 2) gene\n* Patients undergoing neoadjuvant chemotherapy\n* Pregnancy",{"count":496,"type":20},500,"5 Years","This registry trial is designed to track the local control rates and side effects of IORT, which will be implemented for women who are suitable partial breast irradiation (PBI) per the latest American Society of Radiation Oncology (ASTRO) guidelines.",[357],[501,502],"intraoperative radiation therapy","partial breast irradiation","2025-09-18",{"date":505,"type":36},"2025-09-23",{"date":507,"type":36},"2018-08-09",{"date":509,"type":20},"2032-08",{"name":42,"class":43},""]